Press Room

Webinar Series: All you need to know about Continuous Tableting

Start
Wednesday, May 29, 2024 - 16:00
End
Wednesday, July 10, 2024 - 17:00
Location: online
Webinar series - all you need to know about continuous tableting | Hovione

Hovione presents the most comprehensive three-part webinar series on "Opportunities, Challenges and Success in Implementing Continuous Tableting – From R&D to Commercial Manufacturing".

Over the course of this series, Hovione experts and invited speakers from Merck Sharpe & Dohme, Vertex Pharmaceuticals and GEA Group will guide you through the journey of continuous manufacturing (CM) of oral solid dosage forms, also known as continuous tableting (CT), aiming to highlight key opportunities, successes, and challenges with continuous tableting. 

The content of the webinars will cover the role of CM along a wide breadth of the CMC journey, starting with lean and model-based development and concluding with commercial implementation of continuous tableting processes. 

Each session in the series will be presented as a joint talk with participants from innovators like Merck and Vertex Pharmaceuticals, and Hovione, highlighting experiences from each organization and the many advantages of a partnership-based approach. The webinar series will conclude with a final joint talk between GEA Group and Hovione announcing exciting joint innovations in the CT equipment space along with the latest advances in technology simplification.

Featured experts will be available to answer audience questions during a live Q&A after each talk.

SESSION 1 - On-demand

Lean Process Development for Continuous Tableting: Foundations of a Hybrid Approach

The recording is now available.

SESSION 2 - On-demand

Insights from Commercial Implementation of Continuous Tableting: Successes and Challenges of a Partnership-Oriented Approach

Thursday, June 20
11:00 am EDT  |  4:00 pm GMT  |  ​5:00 pm CEST

SESSION 3 - On-demand

Simplification of Continuous Tableting for Accelerated Product Development and Lifecycle Flexibility

Wednesday, July 10
11:00 am EDT  |  4:00 pm GMT  |  5:00 pm CEST

 

 

 

 

 

 

 

 

 

 

 

Find out today if continuous tableting is right for your product. 

The Future is Continuous.

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026